• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Novel 1,5-benzothiazepine derivatives of the formula: wherein R1 is hydrogen or lower alkyl, R2 is hydrogen, lower alkanoyl or benzyl, R3 is hydrogen or lower alkyl and either one of R4 and R5 is hydrogen and the other is chlorine, or a pharmaceutically acceptable acid addition salt thereof are disclosed. In form of pharmaceutical compositions the said derivative (I) and its salt have a potent platelet aggregation-inhibiting activity.
    公开号:SU1632372A3
    申请号:SU853880298
    申请日:1985-04-09
    公开日:1991-02-28
    发明作者:Такеда Микио；Ох-Иси Токуро；Накадзима Хиромити；Нагао Таку
    申请人:Танабе Сейяко Ко., Лтд (Фирма)；
    IPC主号:
    专利说明:

    This invention relates to methods for the preparation of new 1,5-Lentsotiazapine derivatives, namely compounds of general formula I. Vor
    H
     -OR,
    Nz
    CH, CHjX.
    where, when R (is methyl, then Rjz is hydrogen or acetyl; R 3 is methyl, ethyl or propyl and one of R4 or Rr is hydrogen and the other is chlorine; or
    when R is hydrogen, then R4 is hydrogen, RJ is metnl,

    s
    R is chlorine
    H is hydrogen, or their pharmaceutically acceptable acid addition salts.
    These compounds have an action that inhibits the aggregation of blood plates, which is of great importance in the therapeutic baking of thrombosis.
    cue properties. M.p. 107.5-1 ° F, 5 ° C.
    IR, CHC1 llrtjt (cm): 3510 (OH); 1695; 1660 ().
    NMR (ATP14). million dollars: 3.03 (ZN, singlet, SM,); 3.80 (SN, singlet, OCH5); 5.09 (211, single,); 7.29 (5H, single,)
    - 133.3 ° (, 532, methanol).
    Yu (3) 1.7 ml of a 25% methyl bromide
    hydrogen - acetic acid is added to a solution of 1.07 g of Ј (- (- cis-2-) 4-methoxyphenyl (-Z-hydroxy-5 -) 2- (N-benzyloxycarbonyl-M-methnlamino) ethyl (-8-chloro15, 2,3-dihydro-1,5-benzothiazepin-4) 5HJ-it in 2 ml of benzene under ice cooling and the mixture is stirred at room temperature for 2 hours. Then ether is added to the mixture and the end of the invention The development of a method for the preparation of compounds exhibiting strong and prolonged pro-toyatro-trombic activity.
    Example 1. (1) A mixture of 4.6 g - Ј- (gcis-2-) 4-methoxyphenyl (-3-hydroxy-8 chloro-2,3-dihydro-1,5-benzothiaeepin-4) 5I T-one 3.37. g (-2) M-benzyl-I-methyl-amyne / ethyl chloride as hydrochloride, 20 precipitates are collected
    4.2 g of potassium carbonate and 300 l of acetone are heated under reflux for 20 hours. Insoluble substances are 1-4V are removed filtered and the filtrate is evaporated under reduced pressure of 5 to remove the solvent. The residue is converted to its nepxnop-thu, and then recrystallized from ethanol. 7.41 g of a - (- cis-2-) 4-methoxy are obtained by filtration and washed with ether. Water and benzene are added to these precipitates and the mixture is made alkaline with potassium carbonate. The benzene layer is collected, washed with water, dried, and then evaporated to remove the solvent. The simple ether is added to the residue and the crystalline precipitates are collected by filtration and transferred.
    that
    and
    n-hexsln. This gives 0.47 g of G - (- cis-2-) 4-methoxyphenyl (-3-hydroxy-5) 2- (N-methylamino) ethyl-8-chloro-2.3-dna-hydro-1.5- benzotnazepin-4 (5H) it. M.p. 142-145 ° C.
    chgo
    147.7e (, 814, chloroAennl (-3-hydroxy-5-) 2- (K-benzyl-M-methyl-30 krnstalizuyvayut from a mixture of ethyl acetate-amino) ethyl (-8-chloro-2,3-ligidro-1 , 5-benothiazepin-4) perchlorate, mp 161-163 ° C (decomposition).
    (Yuyu 76.4 ° (, 589, metynol).,
    (2) To a heated concomitant cholo-35 dilnk-solution of 4.3 g Ј - (- cis-2) 4-methoxyphenyl (-3-hydroxy-5-) 2- (К-benzyl-. N-methylamino) ethG - 8-chloro-2,3-dihydro-1,5-benzothiazepin-4 (5H) -one in 50 ml of benzene is added dropwise over 40 minutes 15 minutes a solution of 4.55 g of benzyl oxycarbonyl chloride in 10 ml benzene. The mixture is heated under reflux for 1 hour and this mixture is evaporated under reduced pressure to remove the solvent. 30 ml of ethanol and 50 ml of an aqueous solution of sodium hydroxide are added to the residue and the mixture is stirred at room temperature for 2 hours. the mixture 50 is diluted with water, dried and evaporated to remove the solvent. 4.79 g / - (- 1i1C-2 -) - 4 methoxynphenyl (3-hydroxy-5) 2- (H Lensnloxy-rbonne-I-mew) i are obtained
    forms).
    Hydrochlorde
    M.p. 137-1 1 1 ° С (perednatalizovanny of ethanol).
    ((X) 0 - 83.9 ° (, 63, methanol).
    Fumarat.
    Prisms obtained by recrystallization from methanol.
    M.p. 170-172 ° C (decomposition) (00Ј - 75, b (C 1.00) methanol.
    Needles obtained by recrystallization from methanol.
    M.p. 159-1M ° С (decomposition) (cOj - 74.1 (С-0.524, methanol).
    Small plates obtained by recrystallization from water.
    M.p. 145-150 ° C: (shattered).
    Oxalate. So pl., 175-177 ° C (raslotilamino) et l-I-chloro-2,3-dihydro-1.555 live) (recrystallized from blend, enzotnasepip-4 (511) -one.
    The product, purified by preparative thin layer chromatography, shows the following physicochemical dimethylformamide and ethylnagl).
    Succinate. .
    M.p. 125-128 ° С (rlchlohagshe) (recrystallized from ethanol).
    cue properties. M.p. 107.5-1 ° F, 5 ° C.
    IR, CHC1 llrtjt (cm): 3510 (OH); 1695; 1660 ().
    NMR (ATP14). million dollars: 3.03 (ZN, singlet, SM,); 3.80 (SN, singlet, OCH5); 5.09 (211, single,); 7.29 (5H, single,)
    - 133.3 ° (, 532, methanol)
    (3) 1.7 ml 25% methyl bromide
    fallen substances collect
    by filtration and washed with ether. Water and benzene are added to these precipitates and the mixture is made alkaline with potassium carbonate. The benzene layer is collected, washed with water, dried and then evaporated to remove the solvent. The simple ether is added to the residue and the crystalline precipitates are collected by filtration and transferred.
    that
    and
    n-hexsln. This gives 0.47 g of G - (- cis-2-) 4-methoxyphenyl (-3-hydroxy-52- (N-methylamino) ethyl-8-chloro-2.3-day-hydro-1.5-benzotnazepin- 4 (5H) it. Mp. 142-145 ° C.
    chgo
    147.7 e (, 814, chlorine crystallized from a mixture of ethyl acetate
    w) i
    forms).
    Hydrochlorde
    M.p. 137-1 1 1 ° С (perednatalizovanny of ethanol).
    ((X) 0 - 83.9 ° (, 63, methanol).
    Fumarat.
    Prisms obtained by recrystallization from methanol.
    M.p. 170-172 ° C (decomposition) (00Ј - 75, b (C 1.00) methanol.
    Needles obtained by recrystallization from methanol.
    M.p. 159-1M ° С (decomposition) (cOj - 74.1 (С-0.524, methanol).
    Small plates obtained by recrystallization from water.
    M.p. 145-150 ° C: (shattered).
    Oxalate. So pl., 175-177 ° C (decomposition) (recrystallized from a mixture of dimethylformamide and ethylnagl).
    Succinate. .
    M.p. 125-128 ° С (rlchlohagshe) (recrystallized from ethanol).
    1632372
    Hydrobromide N € 0. M.p. 137-138 ° C. Decomposition) (recrystallized from ethanol). Sulfate. M.p. 105-128 0 (recrystallized from a mixture of eta-, nola and water).
    Compounds were prepared using the appropriate starting materials using the procedure described.
    G ± (-cis-2) -) 4-ketoxyphenyl (-oxy-5-) 2- (N-methylamino) ethyl (-8-chloro-2,3-dihydro-1,5-benzothiazepin-4) 51P- he is oxapat.
    M.p. 190-194 ° C (decomposition).
    ten
    The physicochemical properties of this product are identical to those of the product 1-ta obtained in Example 1 (2).
    (2) 2.71 g - (- Cys-2-) 4-methoxyphenyl (3-hydroxy-5-) 2-01-benzyloxycarbonyl N-methylamino) ethyl-8-chloro-2,3-dihydro 1 , 5-benzothiazepin-4 (5H) -one is dissolved in 30 ml of ethanol and the solution is saturated with gaseous hydrogen chloride while cooling with ice. The saturated solution is stirred at room temperature for 20 hours. The solution is evaporated under reduced pressure.
    G ± (-Cis-2-) 4-methoxyphenyl (-3-hydroxy-15 pr below 35 C to remove 5-) 2-C-methylamino) ethyl 3-a-chloro-2,3-leny Solvent. The rest of the solution is hydrohydro-1, 5-benothiazepin-4 (5H) -united in white sol and the extract solution drochloride 1/2 ILO. , P concentrated mixture of IS1T. 137-140 ° С GoO + 83.4 ° (С-Н2 ° - VOD is collected, washed
    About 415 methanol), 20 benzene, alkalinized with carbonate
     dolil and then extracted with chloroform. The extract is washed with water, dried and then evaporated to remove the solvent. 25 nsopropyl ether and crystalline ones, m.p. 138-142 ° C (decomposition). DOS 81.0 (C-1.0 methanol). Ј - (- cis-2-) 4-methoxyphenyl - (- 3-ox-5-) 2- (H-p-propylamino) -8-chloro-2, 3-dihydro-1,5-benothiazepine- 4 (-ZH) -one furmarat, m.p. 126-128 ° C
    - (- cis-2-) 4-methoxyphenyl (-3-hydroxy-5-) 2- (N ethylamino) ethyl-8-hpor-2, H-dihydro-1, 5-benzothiazepin-4 (5H) -one furmarat.
    (decomposition).
    , 2 ° (C-1.0 methanol).
    + (-cis-2-) 4-methoxyphenyl (-3-hydroxy-5-) 2- (N-methylamino) ethyl-9-hpor-2, 3-dihydro-1, 5-benzothiazepin-4 (5H) - he is a hydrochloride.
    M.p. 218-220 ° C (decomposition).
    tQtg + 1.96 ° (, 457 methanol).
    PRI mme R 2. (1) C (-Iis-2-) 4-methoxyphenyl (-3-OXI-5-) 2- (H-benyl-N-ketilamino) ethyl-8-chloro-2, 3-digndro-1,5-benzothiazepin-4 (5H) -one,
    sediment collected by filtration. 1.83 g of (-) - dis-2- (4-methoxyphenyl) -3-hydroxy-5- (2-) N-metalamino (ethyl) - 3-xpor-2,3-dihydrs-1, are obtained 5-benzothiazepn
    30 4 (5H) -one.
    The physicochemical properties of this product are identical to those of the product obtained in Example 1 (3).
    Example (1) A mixture of 3.0 g Ј - (- cis-2-) 4-methoxyphenyl (-3-acetoxy
    5 8-chloro-2, 3-dihydro-1,5-benzothiazepine-4) 5HJ-OHa, 1.9 g of chloro-tα-2- (M-benzyl-methylamino) etklchloride, 3.3 potassium carbonate and 80 ml of acetone The mixture is heated under reflux for 20 hours. Insoluble substances are removed by filtration and the filtrate is evaporated under reduced pressure to remove the solvent. OS40
    The physicochemical properties of this product are identical to those of the product 1-ta obtained in Example 1 (2).
    (2) 2.71 g Ј - (- Cys-2-) 4-methoxyphenyl (3-hydroxy-5-) 2-01-benzyloxycarbonyl-. N-methylamino) ethyl-8-chloro-2,3-dihydro-1,5-benzothiazepin-4 (5H) -one is dissolved in 30 ml of ethanol and the solution is saturated with gaseous hydrogen chloride under ice-cooling. The saturated solution is stirred at room temperature for 20 hours. The solution is evaporated under reduced pressure.
    by form. The extract is washed with water, dried and then evaporated to remove the solvent. Nzopropyl ether and crystalline
    sediment collected by filtration. 1.83 g of (-) - dis-2- (4-methoxyphenyl) -3-hydroxy-5- (2-) N-metalamino (ethyl) - 3-xpor-2,3-dihydrs-1, are obtained 5-benzothiazepn
    4 (5H) -one.
    The physicochemical properties of this product are identical to those of the product obtained in Example 1 (3).
    Example (1) A mixture of 3.0 g Ј - (- cis-2-) 4-methoxyphenyl (-3-acetoxy8-chloro-2, 3-dihydro-1,5-benzothiazepine-4) 5HJ-OHa, 1.9 g chloro-indra-2- (M-benzyl-methylamino) etl chloride, 3.3 g of potassium carbonate and 80 ml of acetone are heated under reflux for 20 hours. Insoluble substances are removed by filtration and the filtrate is evaporated under reduced pressure to remove the solvent. Os
    The stretch-t5 perchlorate obtained from 6 g of its perchlorate is dissolved in ethyl acetate and dissolved in 93 ml of benzene and the solution is washed with water, dried and evaporated to remove the solvent. 2.9 g of Ј - (- nis-2-) 4-methoxyphenyl (-3-acetoxy) -5-) 2- (K-benzyl-K-methylamino) ethyl-2-chloro-2 are obtained. , -dihydro-1,5-bekzoti.chepin-4 (5H) -one in the form of oil.
    warm with reflux. A solution of 5.28 g of benzyloxl-50 -bonyl chloride in 12 ml of benzene is added dropwise to this heated solution under reflux and the mixture is heated under reflux for 4 hours. The mixture is evaporated under reduced pressure to remove the solvent. 5.42 g of {/ - (- cis-2-) 55 4-methoxyphenyl (-3-hydroxy-5-) 2- (N-benzyl-hydroxycarbonyl-M-methyl-amino) chloro-2,3-dihydro are obtained. -1,5-benoothiaeepin-4 (5H) -one.
    The residue is dissolved in ethyl acetate and the solution is washed with water, dried and evaporated to remove the solvent. 2.9 g of Ј - (- nis-2-) 4-methoxyphenyl (-3-acetoxy) -5-) 2- (K-benzyl-K-methylamino) ethyl gH-2-chloro-2 are obtained. , -dihydro-1,5-bekzoti.chepin-4 (5H) -one in the form of oil.
    Oxalat, m.p. 192-194 ° С (decomposition) recrystallized from ethanol. GOG) - 96.5 °. (C-1.0 dimethylformamide).
    (2) A solution of 27.5 g - () L-1mv-toxifennl (-3-acetoc-5-) 2- (H-benzyl-M-methylamino) ethyl-D-I-x;: op., 3-dnglcr -1, 5-benzothiazepn-4 (5H) -on
    600 ml of benzene are heated under reflux, and a solution of 26.2 g of benzyloxycarbonyl chloride in 80 ml of benzene is added dropwise to it over 10 minutes.
    The mixture is heated under reflux for 6 hours. The mixture is then evaporated under reduced pressure.
    to remove the solvent. The residue is washed with n-hexane and thus 37.5 g of (-) - cis-2- (4-methoxynphenyl) -3-acetoxy-5- (2-) H-benzyloxycarbonyl M-methylamino (ethyl) are obtained. -8-chloro-J5 2,3-dihydro-1,5-benothi-eepin-4 (5H) - it is in the form of an oil.
    The product is purified using pre-. para-thin-layer chromatography, shows the following physic-20 chemical properties.
    IR SNSC iUaw CM: 1740, 1685.,
    NMR (CDCl1), min.doll: 1.80 (MN, singlet, OCOCH, j); 3.03 (311, low, CH,); 3.81 OH, singlet, PG.CH,); 5.08 I 25 (211, singlet, C: i2r.); 7.32 (5H, singlet, CgHy).
    OTD, 115.4 (C-1.0 methanol).
    (.3) 37.5 g -1Ns-2-) 4-methoxenf-30nyl (-3-acetoxn-5-) 2- (H-bengsloloxycarbonl-M-netnlaminno) ethnl) -8-chloro 2,3-dihydr o-1, 5-benzotna: kmshn-4 (51) - it, 75 ml 25% -conic mixture of hydrogen bromide - acetic acid n 95 ml s methylene chloride and mixed when cooled with ice n mixture (stirred at room temperature for 3 hours. The mixture is then evaporated under reduced pressure to remove methylene chloride.) Ether is added to the residue and the ether layer is removed by decantation. The precipitates are washed with ether and dissolved in a hearth. The solution is neutralized with carbonate m potassium and extracted with ethyl acetate. The extract is washed with water, the mixture is evaporated to remove the solvent. The residue is converted into its oxalate and recrystallized from methanol. 18.7 g, p-oxalate - (- ccc-2-) 4- methoxynphenyl (-3-acetoxy-g -) 2- (N-mnthllllnno) otyl | - 8-chloro-2, 3-di pdrl-1, 5-ben otnlzepnn-4 (5I) -one.
    M.p. 175-177 C, (shattered), SDO 7 .: °, 8K, methanol). 55 Ig favor MiTo- iHKy given in example 3 and the corresponding materials are obtained.
    G ± (-Cig-2-K -M1 toxifep | g;; - 3 - ace-TOKcn- t-) 2 - (. NaNntHo), -) - chlorine 2,3 dihydro-1,5-benzothiazepine- 4) 5nS-he / 3 1120.
    M.p. 132-4 ° C. COЈ- 0, 5 5 (, 352 methanol).
    G4 (-Hi (C-2-) 4-methoxynphenyl (-Z-acetoxn-5-) 2- (Mm tilaminoEzt l -in- chloro-2,3-dihydro-1,5-bentotnaeepin-4 ( 510-it HYDRES about bromide CZH.OH. 1/2 I., 0, mp 129-131 ° С (decomposition).
    G ± (-Cis-2-) 4-g 1-totoksifennl) (-3-acetoxn-5-) 2 - (N-methylamino) ethyl 3-chloro-2,3, dihydro-1,5-ben othiazepin-4 ( 511) oxalate, 12O.
    T.il. 1 / 2-173 ° C (decomposition). (, 422, methanol).
    I
    Example 5. A solution of 1.5 g,
    Ј - (- cns-2) 4-M (2-toxyphenyl (-3-hydroxy-52- (1 -methyl) 1-I-chloro-2,3-dn-gndro-i, 5-bispiazepiaznn 4 (5I) - It is 50 ml of methyl chloride and is added dropwise to a solution of .77 g of tribromis-Oor in 0 ml of msgilene chloride at -50 ° C for 30 minutes and the mixture is stirred at the same temperature for 30: 1;: H. The mixture is then evaporated at Tet-snepaTX pe below 30 ° C under nominal pressure to remove the solvent. To the residue; ooa riHWT ice-water mixture; suitable sodium bicarbonate solution. Precipitates are collected by fluorine. The precipitates are dissolved in acetone and unresponsible scrubs are removed Og.-chtrat evaporated g; tn ponilopnom chaklenng. for successful-hp rastera zhchstn. The residue preg.ratsyag it cm-o.;...... -.-OksNzzo. blends, and percrystal crystals, and mixtures of ethanote and simple phpra. 1.1. legs 0.80 g (3) 2 hydrates of 2- (4-oxpfennl) 3-hydroxy 5- (2-) p-methylamine ( ty:;) - L-chlorine -.:, 3-digpdro-1, 5-oen: ncht in: 1hm-- (51) -one.
    G.pl. 12 -; - 12 ° C: -197,. O0 (, 55b metschio-i).
    II p and m r p 6. (1) (m, s 2,) g - (-; 01С-2 -) -motoks fen. |, - -gndroxy-8-hdor-2, 3-dngndro, -c, and bruising zoggin- 4) 5 iJ-ona, 2 ,. five) ; . - (. N-ben 911.4-me gi. Chamino) tpl bromide ichropromzgda, 3.74 g of carbonate k.ishch and ISO ml of acetone are heated with Os-p h. odilign kom in the turning of 20 hours ... the alien maternity; s, remove w:, - ;. -.imsm and the filtrate is evaporated .- ,, HMUJ is the pressure for rastgurentlch.
    The residue is converted to perchlorate permeate, after which it is perciphered from ethanol. 3.78 g of G - (- cis-2-) 4-methoxyphenyl (-3-hydroxy-5) 2-j P-br.nlyl-N-methydemino (ethyl) 3-chloro-2, 3- are obtained. dihydro-1, 5-benotinazepin (-4) 5H-he perchlorate.
    The physicochemical properties of this product are identical to the product obtained according to Example 1 (1).
    (2) The product obtained under paragraph (1) is treated in the same manner as indicated in Example 1 (2) and (3), and получают- (cis-2-} 4-methoxyphenle (-3-OXI-5 -) 2- (N-methyl-amino) ethyl-8-chloro-2, 3-dihydro-1,5-benzothiae-4 (511) -one.
    The physicochemical properties of this product are identical to the product obtained in Example 1 (3).
    Example 7. A mixture of 3.3 g of L - (- IDI 2-) 4-methoxyfennl (-Z-hydroxy-8-chloro-2, Z-dihydro-1,5-benzoazepin-4) 5НJ- it, 2.28 g of 2- (M-bennylmethylamino) ethyl chloride hydrochloride, 4.48 g of potassium carbonate, 200 ml of ethylpropionate and 2 ml of water are heated under reflux for 20 hours. Insoluble materials are removed by filtration, and the filtrate is evaporated under reduced pressure to removal of solvent. The remainder is converted into perchlorite corresponding to it, after which the cross-installment of ethanol.
    5.19 g of g is obtained - (- cnc-2-) 4-methoxyphenyl (-3-hydroxy-5-) 2- (M-benzyl-M-methylamino) -ethyl {-8-chloro-2,3 -digndro 1,5-benzothiazepin-4 (5H) -one perchlorate
    The physicochemical properties of this product are identical to the product obtained in example 1 (1).
    The product obtained in (1) is treated in the same manner as described in Example 1 (2) and (3), and 2 - (- cis-2-) 4-methoxyphenyl (-3-hydroxy-5-) 2 is obtained - (M-methylamino) -ethyl | -8 chloro-2,3-digilrate-1,5-benzothiazepin-4 (5H) -one.
    The properties of this product are identical to the product obtained in example 1 (3
    Timed A mixture of 300 mg of Ј - (- - (- cis-2-) 4-methoxyphenyl (-3-hydroxy-8-chloro-2,3-dihydre-1,5-benothiazepin-4 SHJ-one, 3 ml of dimethyl sulfoxide and 15 mg of powdered potassium hydroxide is stirred at room temperature. Then 134 m is added to the mixture.
    five
    g
    five
    0
    0
    five
    five
    0
    five
     - (ll-MC PiYMPPP1 14 CHLORID, 1 I IDROX-Yurnda and chtu mixture of pgrmsgttinlmt at room temperature overnight. The mixture is sewn into a mixture of water with tytylacetate n ng rlgt1 orient 1e chsiygtip ud, pmt filtered. J gc. ; | gh with look around m fplg1) ata. Good gmo; ; extracted with ethyl acetate, and the extracts combined with the ptyacetate layer. Combined solution of 3KCTparnpvwT 10% -noft vi.j -; HYDROXIDE) ACID AND IODINE ELEPHANT
    nod1chchlachayut ka.pi hydroxide. The solution is extracted with chloroform. The Xporoformip bed is washed with water, evaporated and evaporated to remove the solvent. The remainder will turn into its fum-chrat.
    The physico-chemical properties of this product are identical to the product obtained according to example 1 (3).
    Example 12. The out-of-burning effect of the innbitor is organic (ex vivo) on the aggregation of blood plates caused by collagen in the rat blood plates experiment. Solution of the compound used at a dose of 10 MI / kg orala. Spread.ue-Dawley rats left without food for approximately 20 hours. 3 hours after the administration, blood was collected from the abdominal aorta of the rat. Nine volumes of blood are mixed with one volume of an aqueous 3.8% aqueous solution of sodium trisodium citrate and the mixture is centrifuged to give a plasma rich in blood plates (PRP) in the form of a top-melting solution. The bottom layer is further centrifuged, giving the plasma depleted in blood plates (PRP) in the form of a solution melting from above. PRP is diluted with PRP so that the number of blood plates is 0.8-1x10 (ml3 25 µl of collagen solution is added to 225 µl of diluted PRP in order to cause aggregation of the platelets. The degree of plate aggregation is checked by the Born method ( nature 194, 927/1962) and from these data, calculate the percentage of inhibition of aggregation of blood plates. The inhibitory effect of the test compound on aggregation of blood plates induced by collagen is estimated as (-) if the percentage of inhibition is less than 25%, (+) - if percent nt nngibirovani is not less than 25% but mengae 50% and (++) - if the percentage nngnbn- rovapi l was not less than 50%.
    The results are shown in Table. one.
    Example 13. In vitro inhibition of aggregation of blood plates caused by collagen with blood plates of rats. Nine volumes of rat blood are mixed with one volume of 3.8% by weight aqueous solution of tri-sodium citrate. The mixture is concentrated, get the plasma enriched plates (PRP in the form of a floating solution above). The content of blood plates in PPP was adjusted to 0.8-1x10 mm3, diluted with PRP.
    Then a mixture of 200 ml of diluted PCR and 25 µl of the test compound solution is stirred for 2 minutes at 37 ° C and 25 ml of collagen solution is added (see Example 12). The degree of aggregation is tested according to the Born method and the percent inhibition of aggregation of blood plates is calculated.
    The inhibitory effect of the test compound on the aggregation of blood plates caused by collagen is presented as 1Csd (concentration of a test compound that requires the aggregation of blood plates caused by collagen).
    The results are presented in table. 2. In addition, in table. 2 shows the maximum tolerated dose of the test compound.
    As can be seen from the data table. 2 in the case of aggravating platelets, the inhibitory effect of 1C5o was 5-- 17 µg / ml for the compound obtained by the proposed method, but more than 100 µg / mp for known compounds. Thus, the compounds obtained are 5.8 to 20 times stronger than the United States patent in terms of the inhibitory effect. Moreover, the maximum tolerant dose is 100-200 mg (intraperitoneally) for known compounds, while the proposed compounds are superior to
    known compounds in terms of security.
    Consequently, the compounds obtained are superior in all respects to known compounds in terms of their pharmacological activity and toxicity.
    50
    and their use in medicine is the safest.
    Example 14. Inhibitory effect on excited call55
    platelet aggregation genome in rat rat plates. 9 oP-cyan krp blue blood is mixed with 1 volume of 3.8 wt.% Trisodium citric acid and the mixture is centrifuged, which barks plasma enriched with plasma platelets (PRP) in the form of a floating solution. The counted amount in PRP is set at about 0.8 to 1x10 / mm3 by diluting the PRP.
    After 2 minutes of stirring at 37 a mixture of 200 µl of diluted PRP and 25 µl of the test compound solution, 25 µl of the collagen solution was added to the mixture. The degree of platelet gregregation is examined by the Bohr method and, based on the data obtained, the percentage inhibition of platelet aggregation is calculated.
    The inhibitory effect of the test compound on collagen-induced platelet aggregation is determined by the ICg values (i.e. the concentration of test compound required to arouse 50% inhibition of collagen-induced platelet aggregation).
    The results and the maximum tolerated doses of the tested compounds are shown in Table. 3
    Thus, as can be seen from the table. 1-3 data, the compounds obtained by the proposed method have a strong activity of inhibiting the aggregation of blood platelets and can be useful for treating, alleviating or preventing thrombotic diseases such as cerebral infrastructure (or cerebral thrombosis), transient cerebral ischemia, myocardial infarction (or coronary thrombosis), pulmonary infarction, peripheral vascular embolism, thromboangitis and / or other thromboembolism (for example, thrombo-embolism resulting from a displacement of the heart valve.
    The therapeutic dose of the obtained compound (1) or a salt thereof depends on the method of administration of the drug, the age, weight and condition of the patient and on the specific diseases to be treated. Usually, however, it can be used in a dose of from 0.05 to 50 mg / kg / day, in the case of parenteral administration (for example, by intravenous injection).
    uk
    F o rm y l l invented and
    Method for the preparation of 1,5-benzothiazepine derivatives of general formula I
    OR
    1Л1
    sn2sn2;
    n3 n
    when R is methyl, then R is hydrogen shsh acetyl; R.J is methyl, ethyl or propyl and one of R n R is hydrogen and the other is chlorine;
    or,
    when R. is hydrogen, then AND is hydrogen, RJ is methyl, R is chlorine, RC is hydrogen,
    or their pharmaceutically acceptable acid addition salts, characterized in that the compound of the general formula II
    R
     XX OR
     about to °
    where R is hydrogen RTH acetyl;
    R4
    and Rj is one hydrogen, the other chlorine is subjected to condensation with a hydrochloride or hydrobromide compound of the general formula III
    / R3 X - CH2CH2N С
    where Q is hydrogen or a benelyl protecting group; R3 is methyl, ethyl or propyl;
    X is chlorine or bromine, in the medium of a solvent in the presence of a base at 25-100 ° C to obtain compounds of general formula IV
    OCHj
    CHjCHjNv
    g, f R - I ,, and another vK.ii.iHHiie is significant, ti h-ie,; vi ii l4 remote, if they get connected by a formula I, where Rц - mstn., 1, Yag - R have indicated banners , the final group, when Q is a nutrient group, and / or the introduction of the target compound in free form or as a pharmacist. my acid-additive honeycombs, or Psuchoo j :::: compounds of the general formula la,
    HE
    5, G
     N o
    CH2Gi2N / 3
    Nh GDR R h - methyl;
    R ,, - humor;
    R is hydrogen,
    dimethylinvolve corresponds to the joint in common; Formula I, where R is methyl, RJ, is hydrogen, Yats. - chlorine, R hydrogen, by treating with three-boron boron in the medium of an organic solvent at -5 ° C with a precipitating release of combs of formula 1a in a free form — lice in the form of a pharmacologically admixed mono acid addition salt.
    Table 1
    Compounds
    The activity of ngibirovaniya aggregation of platelets
    40
    - (-ipic-2-) 4-methoxy-phenyl (-Z-hydroxy-5-) 2- (N-methylamino) ethyl - 8-chloro-2, Z-dihydro-1,545 benzothiazepin-4 (51i) -oH . H- (cis-2-) 4-methoxyphenyl (-3-acetoxy-5-) 2- (N-methylamino) ethyl -850 chloro-2,3-dihydro-1,5-benzothiazepin-4 hydrochloride ( 5H) -one oxalate.
    + (- cis-2-) 4-methoxyphenyl (-3-oxit-5-) 2- (M-me55 tilamino) ethyl 7-9-chloro-2, 3-dihydro-1,5-benzothiazepin-4 (5H) -one. hydrochloride
    ++
    ++
    ++
    Compounds
    Compounds prepared by the proposed method.
    Ј- (cis-2-) 4-methoxyphenyl (-3-OXI-5-) 2- (H-methylamino ethyl-8-chloro-2,3-dihydro-1,5-benzothiazepin-4 (5H) -one furmarat
    Ј + (- cis-2-) 4-methoxyphenyl (-3-OXY-5-) 2- (M-methyl-amno) ethyl-9-xpor-2,3-dihydro-1,5-benothiazepine - 4 (5H) -one hydrochloride
    Ј - (- cis-2-) 4-methoxy-phenyl (-Z-acetoxy-5-) 2-. (N-methylamino) eotor-213-dihydro-1,5-benzothiazepin-4 (5H) -one 1/3 hydrochlorporide Known compounds
    - (- cis -.-) 4-methoxy-phenyl (-Z-acetoxy-5-) 2- (dimethylamino) chloro-2,3-dihydro-1,5-benzothiazepin-4 (5H) -one hydrochloride
    Ј - (- cis-2-) 4-methoxyphenyl (-Z-hydroxy-5-) 2- (dimethylamino) chloro-2,3-dihydro-1, 5-benzothiazepin-4 (5H) -one (free base)
    W -j "n
    . ъ
    and y .4,
    g- "t. G, v% 2

    Toxicity
    (tolerant dose of test compound)
    200
    100
    100
    thirty
    100
    Compounds
    Compounds prepared according to the invention.
    T (-cis-2-) 4-hydroxyphenyl
    (3-hydroxy-5-).-N- (methylamine) ethyl-3-chloro-2,3-dihydro-1,5-benzothiazepin-4 (5H) -on-2 (4-hydroxybenzoyl) salt of benzoic acid 3 / 2 H2015
    Ј - (- cis) -2- (4-methoxy-phenyl) -3-OKCH-5-2-N- (ethyl-amino) ethyl (-3-chloro-2.3) di-hydro-1.5 -benzothiazepine (-4) 5H -on fumarate15
    - (- cis-2-) 4-methoxy-phenyl (-3-OXI-5-) 2- (propylamino) ethyl (-8-chloro-2,3-dihydro-1,5-benzothia- v zepine 4) 5n3-he fumarate 40
    Known compounds
    - (cis-2-) 4-methoxy-phenyl (-3-OXI-5-) 2- (di-, methylamino) ethylZ-2-xpor-2, 3-dihydro-1,5-benzothiazepin-4 (5H) -onbol
    (free base)
     С (ТЧС-2) 4-methoxy- .i phenyl (-3 acetoxy-3-) 2-Oschzelin-4) 5 G | -one hydrochloride more than 10030
    Table3
    Inhibitory action against platelet adhesion
    1C jo
    (µg / mp)
    10E
    100
    more than, 390
    权利要求:
    Claims (2)
    [1]
    The method of obtaining derivatives of 1,5benzothiazepine of the general formula I sn 2 sn 2 and ί where, when
    R is methyl, then R is hydrogen or acetyl; Rj is methyl, ethyl or propyl and one of R 4 and Rj is hydrogen and the other is chlorine;
    g ;; e R z - 2 and H have '· the indicated values with 1'.> eld ^ t) G'lm by removal if a compound of the general formula I is obtained, where R 4 is revenge, R z is R have the indicated meaning ; closed group, when Q is a protective group, p / or isolation of the target compound in free form or in the form of Pharmaceutically acceptable acid addition s.'Sh, or in the case of psnune :::::; compounds of General Formula 1a
    And 5 ! 'AND "CH z CH 2 N X 3 ''h or, when
    R 4 is hydrogen, then R-2 is hydrogen, Rj is methyl, R 4 is chlorine, R - hydrogen, or their pharmaceutically acceptable acid addition salts, wherein the compound of general formula II is methyl; chlorine;
    hydrogen, dimethylnomer of the corresponding compound of general formula I, where R | methyl, Rj, - hydrogen, 1 < + - chlorine, Ry “hydrogen, by treatment with boron tribromide in an organic solvent at -59 ° C followed by isolation of the compound of general formula 1a in free form or in the form of a pharmaceutically acceptable acid addition salt.
    Table 1
    Compounds where is hydrogen or acetyl;
    R 4 and Ry are one hydrogen and the other is chlorine; subjected to condensation with hydrochloride or hydrobromide compounds of the formula III
    Inhibition activity of blood platelet aggregation of (-cis-2—) 4-methoxyphenyl (-Z-hydroxy-5-) 2 (N-methylamino) onuij 8-chloro-2, 3-dihydro-1,5benzothiazepin-4 (5H) - it.
    ’Hydrochloride £ - (cis-2—) 4-methoxyphene - nip (- 3-acetoxy-5-)
    [2]
    2 (N-methylamino) -ethyl ^ -8xpor-2,3-dihydro-1,5benzothiazepin-4 (5H) -one oxalate [+ (- cis-2-) 4 ~ methoxyphenyl (-3-oxit5-) 2- (Y-me55 typical) ethyl J-S-chloro 2, 3-dihydro-1,5-benzothia · = zepin-4 (5H) -one hydrochloride
    Q
    Q is hydrogen or a benzyl protecting group;
    Rj is methyl, ethyl or propyl; X is chlorine or bromine, in a solvent medium in the presence of a base at 25-100 ° C to obtain compounds of the general formula IV where ++ ++
    I ++
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1632372A3|1991-02-28|Method for preparing 1,5-benzothiazepine derivatives or their pharmaceutically acceptable acid-additive salts
    SU1349700A3|1987-10-30|Method of obtaining | oxyalkylamides,their optical isomers or pharmaceutically acceptable salts with acids
    EP1019370B1|2003-01-02|Ace-inhibitor nitric salts
    US7550507B2|2009-06-23|2-| benzoate and its preparation and use
    US3818035A|1974-06-18|2{8 |METHYL{9 -{66 {11 IMIDAZOLINE
    EP0288973B1|1993-01-13|Benzothiazolinone derivatives, their production and pharmaceutical composition
    EP0288176A1|1988-10-26|Tyrosine derivatives and use thereof
    PT1133474E|2007-04-30|3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
    JP2001507676A|2001-06-12|Antithrombotic organic nitrate
    NZ274848A|1998-03-25|2-n-amidinocarbamoyl-3-aminopiperazine derivatives substituted by a phenyl substituted piperazinyl moiety
    SU1609443A3|1990-11-23|Method of producing n-/2-|-1methyl/-ethyl-n-methyl-n-propylamine as racemate or l-isomer, or their salts
    SU1609451A3|1990-11-23|Method of producing derivatives of dihydrobenzfurane- or chromane-carboxamides or their additive pharmaceutically acceptable salts
    JP4281993B2|2009-06-17|Substituted heterocyclic-norbornylamino derivatives, their preparation, their use as pharmaceuticals or diagnostics, and pharmaceuticals containing them
    PT86369B|1990-11-20|PROCESS FOR THE PREPARATION OF NEW DERIVATIVES OF 5-PENTILAMINO-5-OXOPENTANOIC ACID AND 4-PENTILAMINO-4-OXOBUTANOIC ACID WITH ANTAGONIC ACTION IN RELATION TO COLECISTOQUININE
    WO2020020231A1|2020-01-30|Two-quaternary ammonium compound and preparation method and use thereof
    DD239202A5|1986-09-17|PROCESS FOR THE PREPARATION OF 9-CHLORO-1,5-BENZOTHIAZEPINE DERIVATIVES
    WO2000053208A2|2000-09-14|Small molecules having glp-2 like activity
    PT85280B|1990-03-30|PROCESS FOR THE PREPARATION OF {2- | -ETIL} - {2 - {{2- | -PHENYL} - | -AMINO} -2-OXO-ETHYL} -CARBAMATES OR UREES AND COMPOSITIONS PHARMACEUTICAL CONTAINERS
    IE44588B1|1982-01-27|Trans-4-heterocyclyl-3,4-dihidro-2h-benzo|pyran-3-ol esters
    PT99672A|1992-10-30|PROCESS FOR THE PREPARATION OF SUBSTITUTED N-BENZOYL-N &#39;- | -PYERAZINES
    FI56679C|1980-03-10|3-AMINO-2,4,6-TRIJODPHENYL- ELLER-BENZOYLALCANSYROR SOM ANVAENDES SOM ROENTGENKONTRASTMEDEL OCH DESSA FOERENINGARS FARMACEUTISKT GODTAGBARA SALTER
    PT89227B|1993-07-30|PROCESS FOR THE PREPARATION OF ANTI-HYPERTENSIVE AGENTS BASED ON MERCAPTO-ACYLAMINO-ACIDS
    EP2010481A1|2009-01-07|Type 1, 4-naphtoquinone compounds, compositions comprising them and use of these compounds as anti-cancer agents
    LU82797A1|1982-05-10|NOVEL 2-AMINO-BENZOYL-3 PHENYLACETAMIDES AND THEIR CYCLIC HOMOLOGUES USEFUL AS MEDICAMENTS AND THERAPEUTIC COMPOSITIONS AND PHARMACEUTICAL FORMS CONTAINING THEM
    US6071968A|2000-06-06|Phenylenediamine derivative radical scavenger, brain-infarction depressant, and brain-edema depressant
    同族专利:
    公开号 | 公开日
    ES8801230A1|1988-01-01|
    ES542125A0|1987-05-01|
    US4585768A|1986-04-29|
    HU191785B|1987-04-28|
    HUT37411A|1985-12-28|
    ES8705408A1|1987-05-01|
    EP0158339B1|1989-01-18|
    AU572978B2|1988-05-19|
    CA1218991A|1987-03-10|
    KR850007248A|1985-12-02|
    DK157785A|1985-10-11|
    SU1358784A3|1987-12-07|
    EP0158339A3|1986-06-11|
    KR910005414B1|1991-07-29|
    ES557061A0|1988-01-01|
    DK157785D0|1985-04-09|
    EP0158339A2|1985-10-16|
    JPH0374659B2|1991-11-27|
    AT40126T|1989-02-15|
    DK172257B1|1998-02-09|
    DE3567650D1|1989-02-23|
    JPS60226866A|1985-11-12|
    AU4039285A|1985-10-17|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3075967A|1961-06-12|1963-01-29|Olin Mathieson|Benzothiazines|
    US3341519A|1965-04-28|1967-09-12|Squibb & Sons Inc|Novel benzoxazines, benzothiazines, benzoxazepins and benzothiazepins|
    GB1236467A|1967-10-28|1971-06-23|Tanabe Seiyaku Co|Benzothiazepine derivatives|
    US3562257A|1967-10-28|1971-02-09|Tanabe Seiyaku Co|Benzothiazepine derivatives|
    JPS6317044B2|1980-05-02|1988-04-12|Tanabe Seiyaku Co|
    JPS6317045B2|1980-05-02|1988-04-12|Tanabe Seiyaku Co|
    US4567175A|1983-06-03|1986-01-28|Tanabe Seiyaku Co., Ltd.|8-Chloro-1,5-benzothiazepine derivatives|
    GB8316032D0|1983-06-11|1983-07-13|Tanabe Seiyaku Co|Benzothiazepine derivatives|
    CH665909A5|1985-05-15|1988-06-15|Matix Ind Sa|METHOD AND DEVICE FOR ULTRASONIC DETECTION OF INTERNAL DEFECTS OF A RAILWAY RAIL LOCATED IN THE EDGE OF THE MUSHROOM OF THAT RAIL, USE OF THE DEVICE.|
    US5708066A|1995-03-01|1998-01-13|E. I. Du Pont De Nemours And Company|Reaction curable composition and solid surface material|GB2167063A|1984-11-17|1986-05-21|Tanabe Seiyaku Co|6 or 9-chloro-1, 5-benzothiazepine derivatives|
    JPH0573749B2|1986-01-07|1993-10-15|Tanabe Seiyaku Co|
    JPH0573728B2|1986-05-23|1993-10-15|Tanabe Seiyaku Co|
    US4729994A|1986-08-20|1988-03-08|Mcneilab, Inc.|Benzothiazepine vasodilators having aralkyl substitution|
    FR2624117B1|1987-12-08|1991-02-22|Synthelabo|HYDROXY-3-2-5 DIHYDRO-2,3 5H-BENZOTHIAZEPINE-1,5 ONE-4 DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION|
    FR2630107B1|1988-04-19|1990-06-08|Synthelabo|PROCESS FOR THE PREPARATION OF- THIO) -3 HYDROXY-2-3 METHYL PROPIONATE|
    NL8801311A|1988-05-20|1989-12-18|Stamicarbon|PHENYL GLYCIDATE STEREOISOMERS, CONTAINING PRODUCTS THEREOF WITH 2-NITROTHIOPHENOL AND THE PREPARATION OF DILTIAZEM.|
    FI95931C|1988-09-02|1996-04-10|Tanabe Seiyaku Co|Process for the preparation of the lower alkyl ester of-3-glycidic acid|
    FR2637285B1|1988-10-03|1991-04-12|Synthelabo|PROCESS FOR THE PREPARATION OF PROPIONIC ACID DERIVATIVES AND PRODUCTS OBTAINED|
    US6521445B1|1988-10-26|2003-02-18|Sepracor, Inc.|Process for preparing optically active glycidate esters|
    US5274300A|1988-10-26|1993-12-28|Sepracor, Inc.|Enzymatic hydrolysis of glycidate esters in the presence of bisulfite anion|
    FR2642425A1|1989-01-30|1990-08-03|Sanofi Sa|PROCESS FOR THE PREPARATION OF BENZOTHIAZEPINE-1.5 ONE-4 DERIVATIVES|
    JP2674232B2|1989-08-31|1997-11-12|田辺製薬株式会社|1,5-benzothiazepine derivative|
    JPH088879B2|1989-09-13|1996-01-31|田辺製薬株式会社|Process for producing optically active 3-phenylglycidate compounds|
    US5250679A|1991-10-18|1993-10-05|Genentech, Inc.|Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor|
    US5663166A|1991-10-18|1997-09-02|Genentech, Inc.|Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor|
    JP2643798B2|1992-10-23|1997-08-20|田辺製薬株式会社|Peripheral arterial blood flow enhancer|
    FR2704848B1|1993-05-03|1995-07-21|Prod Chim Auxil Synthese|Liquid precursor for the production of fluorine-doped tin oxide coatings and corresponding coating process.|
    US5580867A|1994-09-09|1996-12-03|Universite De Montreal|Myocardial protection during ischemia and reperfusion|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB8409258|1984-04-10|
    [返回顶部]